⌕
Conmed · CNMD · NYSE
Tenet 56 · Mixed
Compare
$48.39−1.95%At closeTenet 56 · Mixed
$48.39−0.96 (−1.95%)
At close: Nov 17, 2026, 4:00 PM ET· NYSE · USD

Conmed (CNMD) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue compounds ~8.0%/yr (FY21→FY25), net margin 3.4%, and free cash flow (~$150.9M) tracks net income. Earnings are cash, not paper. Worth your attention in FY25: Capex step-up ($19.8M). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)▲5.2%
1,374.7
FY21→FY25CAGR +8.0%/yr
Net income ($M)▼64.5%
47.1
one-off year: see footnoteCAGR −6.9%/yr
Free cash flow ($M)▼2.0%
150.9
capex stepped upCAGR +11.7%/yr
Diluted EPS▼64.5%
1.51
FY21→FY25CAGR −6.1%/yr
What the receipts whisper · what a headline number hides
Share count
+4.8%

29.4mn → 30.8mn diluted shares since FY21. Broadly flat, so EPS moves with net income rather than with the share count.

Capex step-up
$19.8M

▲51% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)1374.7Revenue−624.2COGS750.5Gross profit−55.9R&D−592.0SG&A102.6Op income−55.6Tax & other47.1Net income

3¢ of every revenue dollar becomes profit. The biggest cost lever is operating expenses.

Margin trend · direction beats level Gross Operating Net
604530150%sector median net margin ~3%FY21FY25

Over this window: gross 56.2% → 54.6%. Net margin 3.4% is above the sector median.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
1,369.31,374.71,307.01,244.71,045.51,010.6▲5.2%+8.0%
Cost of revenue
581.0624.2574.0568.5474.2442.6▲8.8%+9.0%
Gross profit
788.3750.5733.0676.2571.2568.0▲2.4%+7.2%
Research & development
62.355.954.452.647.243.6▲2.7%+6.4%
Selling, general & admin
590.4592.0478.3503.0454.0414.8▲23.8%+9.3%
Total operating expenses
652.7647.9532.7555.6501.2458.3▲21.6%+9.0%
Operating incomefeeds ROC rank
135.6102.6200.3120.670.1109.7▼48.8%−1.7%
Other income, net
−30.6−31.5−37.3−39.8−140.9−36.6——
Pretax income
105.071.1163.080.8−70.973.1▼56.4%−0.7%
Income tax
31.524.130.616.49.710.6▼21.4%+22.9%
Net incomePiotroski ROA ✓feeds Buffett Quality owner earnings
73.447.1132.464.5−80.662.5▼64.5%−6.9%
Per share
Diluted EPSbuyback-sensitive
2.421.514.252.04−2.681.94▼64.5%−6.1%
Diluted shares (mn)
30.1330.8330.9130.7830.5029.41▼0.2%+1.2%
Margins
Gross margin38th pct in Healthcare
57.6%54.6%56.1%54.3%54.6%56.2%▼1.5pp−1.6pp
Operating margin
9.9%7.5%15.3%9.7%6.7%10.9%▼7.9pp−3.4pp
Net margin56th pct in Healthcare
5.4%3.4%10.1%5.2%−7.7%6.2%▼6.7pp−2.8pp
† TTM = trailing four quarters through 2026-09-30.FY22 effective tax rate was −14% vs a 19% norm for this window, likely a one-time item; see the filing.FY25 effective tax rate was 34% vs a 19% norm for this window, likely a one-time item; see the filing.
FY09 – FY20 · 12 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 12 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-17 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Conmed's revenue last fiscal year?

Conmed reported revenue of $1,374.7M in fiscal 2025, up 5.2% from fiscal 2024.

What was Conmed's net income?

Conmed reported net income of $47.1M in fiscal 2025, a net margin of 3.4%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.